Ublituximab: Difference between revisions
Content deleted Content added
m Disambiguated: phase 3 → phases of clinical research |
updated from phase 2 clinical trials in MS to phase 3 clinical trials, with reference |
||
Line 45: | Line 45: | ||
'''Ublituximab''' is an immunomodulator. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref> |
'''Ublituximab''' is an immunomodulator. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref> |
||
It is currently in [[phases of clinical research|Phase |
It is currently in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>https://clinicaltrials.gov/ct2/show/NCT03277261</ref> |
||
It is also in Phase 3 clinical trials for [[chronic lymphocytic leukemia]]. |
It is also in Phase 3 clinical trials for [[chronic lymphocytic leukemia]]. |
Revision as of 16:31, 14 June 2018
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is currently in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in Phase 3 clinical trials for chronic lymphocytic leukemia.
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ https://clinicaltrials.gov/ct2/show/NCT03277261